Key Stats for Procter & Gamble Stock
- 52-Week Range: $137.6 to $171.7
- Current Price: $145.2
- Street Mean Target: $165.8
- Street High Target: $186
- TIKR Model Target (Dec. 2030): $200.4
What Happened?
Procter & Gamble (PG), the Cincinnati-based consumer goods giant behind Tide, Pampers, and Gillette, is navigating a deliberate reset: the stock trades near $145 after losing roughly 15% from its 52-week high, while the company’s operational playbook shows an international business that has already begun accelerating and a U.S. portfolio where targeted innovation rollouts are starting to move the needle.
The Q2 fiscal 2026 earnings release on January 22 surfaced the clearest picture of where the softness is concentrated: North America organic sales fell 2%, weighed down by roughly 2 points of base-period inventory distortion tied to port strikes and hurricanes in late fiscal 2025, while every major region outside the U.S., including Latin America at 8% organic growth and Greater China at 3%, either grew or accelerated.
The most important single number from the quarter was not the organic sales result but the operating mechanism behind it: CFO Andre Schulten confirmed that Family Care, Baby Care, and Feminine Care bore the heaviest base-period impact, and that January data for Family Care had already turned positive, including share gains, suggesting the inventory distortion was beginning to clear on the company’s projected timeline.
Shailesh Jejurikar, President and Chief Executive Officer, stated on the Q2 2026 earnings call that “the business is inflecting where we have put these interventions in place,” citing Tide original liquid going from declining to double-digit growth in the three months following its biggest product upgrade in over two decades, and Downy Intense in Mexico delivering double-digit organic sales growth and over 4 points of value share gains since launch.
Looking across the next 3 to 5 years, P&G is running three structural plays simultaneously: national expansion of Tide evo (a concentrated laundry unit protected by over 50 granted patents), a consumer data and AI platform built around petabytes of proprietary behavioral data, and a plan to return approximately $15 billion to shareholders in fiscal 2026 via $10 billion in dividends and $5 billion in buybacks, each anchored to the company’s ambition to reinvent the CPG model from the ground up.
Wall Street’s Take on PG Stock
Q2’s soft U.S. organic number was largely a known distortion; the more consequential signal is whether P&G’s second-half innovation launches convert to durable U.S. share recovery, which would reset forward EPS estimates upward.
PG’s normalized EPS is forecast to reach $6.96 in fiscal 2026 and $7.28 in fiscal 2027, building on $6.83 in fiscal 2025, a trajectory anchored to the Tide evo national rollout, Olay U.S. relaunch, and accelerating Enterprise Market momentum already running at mid-single digits.
Nine buy-rated analysts and five outperforms sit alongside nine holds and one underperform, with a mean price target of $165.82 and a high target of $186, implying the Street sees 14% to 28% upside from current levels; what Wall Street is waiting on is U.S. market share stabilization exiting fiscal 2026 and a clear reacceleration signal heading into fiscal 2027.
The $142 low target reflects a bear case where U.S. consumer softness deepens and innovation launches fail to generate trial; the $186 high target reflects a scenario where Tide evo distribution scale and the Olay relaunch drive meaningful share recovery, with the data expected at the April 24 Q3 fiscal 2026 earnings webcast serving as the clearest near-term resolution.
Trading at approximately 20.9x fiscal 2026 normalized EPS of $6.96, Procter & Gamble stock sits below its five-year historical forward P/E average of roughly 24x, even as EPS growth is forecast to accelerate from 1.9% in fiscal 2026 to 4.6% in fiscal 2027, leaving Procter & Gamble stock appearing undervalued against a base of improving earnings momentum and a balance sheet returning $15 billion to shareholders this fiscal year.
If U.S. consumer demand deteriorates further and promotional intensity from private-label and category challengers intensifies, the U.S. organic sales recovery embedded in second-half guidance fails to materialize.
The April 24 Q3 fiscal 2026 earnings call is the single event to watch: U.S. organic sales growth turning positive and market share holding or improving would confirm the thesis; a third consecutive quarter of U.S. share loss would break it.
Procter & Gamble Stock Financials
Procter & Gamble generated $84.3 billion in revenue for fiscal 2025, essentially flat versus fiscal 2024, marking the sharpest growth deceleration in the past five years after the company posted 2.5% and 2.3% revenue growth in the two prior periods.
Operating income reached $21.6 billion in fiscal 2025, up 3.2% year over year, supported by the company’s productivity savings program delivering 270 basis points of gross efficiency in Q2 alone, even as gross margins compressed slightly to 51.3% from 51.7% in fiscal 2024.
The operating leverage story is directionally intact: operating margins expanded from 24.9% in fiscal 2024 to 25.6% in fiscal 2025, and the LTM figure of 25.6% suggests the underlying profitability structure has held even through the U.S. volume softness that characterized the first half of fiscal 2026.
What Does the Valuation Model Say?
The TIKR model’s mid-case target of $200.37, against a current price of $145.16, is built on revenue growing at a 3.4% CAGR through fiscal 2030 and net income margins expanding to 20.1%, both of which are conservative relative to the company’s own fiscal 2026 guidance range and the operating leverage already visible in the income statement.
PG appears undervalued at current levels, trading at a roughly 28% discount to the TIKR mid-case target despite a balance sheet returning $15 billion to shareholders annually and a forward EPS growth curve accelerating from 1.9% in fiscal 2026 to 4.6% in fiscal 2027.
Whether Procter & Gamble stock re-rates toward the $186 Street high or stalls near $145 depends entirely on one variable: whether the U.S. innovation launches convert to measurable market share recovery by the time fiscal 2026 closes.
Base Case / Upside
- Tide evo national expansion is on track per February CAGNY commentary; presale is live and in-store distribution was expected within weeks of the February 19 presentation
- Tide original liquid has already moved from declining to double-digit growth in the three months post-relaunch, on one of the highest-volume SKUs in the portfolio
- Enterprise Markets growing mid-single digits with Latin America at 8% organic and Greater China at 3% provide a demand floor even if U.S. softness persists into Q3
- Normalized EPS of $7.28 in fiscal 2027 represents a 4.6% gain over the fiscal 2026 estimate; at a 23x forward multiple (still below the five-year average), PG would trade at approximately $167
- TIKR model high case of $235.54 assumes 3.8% revenue CAGR and 21.2% net income margins, a scenario that becomes plausible if Tide evo and the Olay relaunch both reach full distribution scale
Downside Risk
- U.S. organic sales in H2 fiscal 2026 were modeled on approximately 2% category value growth; further consumer pullback driven by energy inflation or labor market deterioration could push category growth below that baseline
- TD Cowen downgraded PG to hold in January, citing muted U.S. pricing power and rising resin costs from energy-related input inflation; the brokerage also flagged new U.S. immigration limits as a potential structural cost headwind for the home and personal care sector
- Global aggregate value share was down 20 basis points in the first half of fiscal 2026; sustained share loss over two more consecutive quarters would pressure the consensus mean target of $165.82 toward the $142 Street low
- The TIKR model low case of $165.33 assumes only a 3.1% revenue CAGR and 18.9% net income margins, implying that any material miss on the productivity savings program collapses the target price toward current trading levels
Should You Invest in The Procter & Gamble Company?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up PG stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track The Procter & Gamble Company alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze PG stock on TIKR for Free →
